|
[1]
|
Gonzalez-Lugo, J.D., Chakraborty, S., Verma, A., et al. (2021) The Evolution of Epigenetic Therapy in Myelodysplastic Syndromes and Acute Myeloid Leukemia. Seminars in Hematology, 58, 56-65. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Lee, E., Koh, Y., Hong, J., et al. (2021) Recent Clinical Update of Acute Myeloid Leukemia: Focus on Epigenetic Therapies. Journal of Korean Medical Science, 36, e85. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Wang, B., Guan, W., Lv, N., et al. (2021) Genetic Features and Ef-ficacy of Decitabine-Based Chemotherapy in Elderly Patients with Acute Myeloid Leukemia. Hematology, 26, 371-379. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Stahl, M., Menghrajani, K., Derkach, A., et al. (2021) Clini-cal and Molecular Predictors of Response and Survival Following Venetoclax Therapy in Relapsed/Refractory AML. Blood Advances, 5, 1552-1564. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Pollyea, D.A., Pratz, K., Letai, A., et al. (2021) Veneto-clax with Azacitidine or Decitabine in Patients with Newly Diagnosed Acute Myeloid Leukemia: Long-Term Follow-Up from a Phase 1b Study. American Journal of Hematology, 96, 208-217. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Kayser, S. and Levis, M.J. (2022) Updates on Targeted Therapies for Acute Myeloid Leukaemia. British Journal of Haematology, 196, 316-328. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Sébert, M., Renneville, A., Bally, C., et al. (2019) A Phase II Study of Guadecitabine in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia after Azacitidine Failure. Haematologica, 104, 1565-1571. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Daher-Reyes, G.S., Merchan, B.M. and Yee, K.W.L. (2019) Guadecitabine (SGI-110): An Investigational Drug for the Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia. Expert Opinion on Investigational Drugs, 28, 835-849. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Dittmann, J., Haydn, T., Metzger, P., et al. (2020) Next-Generation Hypomethylating Agent SGI-110 Primes Acute Myeloid Leukemia Cells to IAP Antagonist by Acti-vating Extrinsic and Intrinsic Apoptosis Pathways. Cell Death & Differentiation, 27, 1878-1895. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Garcia-Manero, G., Odenike, O., Amrein, P.C., et al. (2016) Successful Emulation of IV Decitabine Pharmacokinetics with an Oral Fixed-Dose Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine, in Subjects with Myelodysplastic Syndromes (MDS): Final Data of Phase I Study. Blood, 128, Article No. 114. [Google Scholar] [CrossRef]
|
|
[11]
|
Kipp, D. and Wei, A. (2021) The Path to Approval for Oral Hypomethylating Agents in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Future Oncology, 17, 2563-2571. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Wei, A.H., Döhner, H., Pocock, C., et al. (2020) Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. The New England Journal of Medicine, 383, 2526-2537.
|
|
[13]
|
San José-Enériz, E., Gimenez-Camino, N., Agirre, X., et al. (2019) HDAC Inhibitors in Acute Mye-loid Leukemia. Cancers (Basel), 11, 1794. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
DeAngelo, D.J., Walker, A.R., Schlenk, R.F., et al. (2019) Safety and Efficacy of Oral Panobinostat plus Chemotherapy in Patients aged 65 Years or Younger with High-Risk Acute Myeloid Leukemia. Leukemia Research, 85, Article ID: 106197. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Mims, A.S., Mishra, A., Orwick, S., et al. (2018) A Novel Regimen for Relapsed/Refractory Adult Acute Myeloid Leukemia Using a KMT2A Partial Tandem Duplication Targeted Therapy: Results of Phase 1 Study NCI 8485. Haematologica, 103, 982-987. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Jiang, X., Jiang, L., Cheng, J., et al. (2021) Inhibition of EZH2 by Chidamide Exerts Antileukemia Activity and Increases Chemosensitivity through Smo/Gli-1 Pathway in Acute Mye-loid Leukemia. Journal of Translational Medicine, 19, Article No. 117. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Wang, L., Luo, J., Chen, G., et al. (2020) Chidamide, Decitabine, Cytarabine, Aclarubicin, and Granulocyte Colony-Stimulating Factor (CDCAG) in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Single-Arm, Phase 1/2 Study. Clinical Epigenetics, 12, Article No. 132. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Li, Z., Zhang, J., Zhou, M., Li, J.L., et al. (2022) Epigenetic Therapy with Chidamide Alone or Combined with 5-Azacitidine Exerts Antitumour Effects on Acute Myeloid Leukaemia Cells in Vitro. Oncology Reports, 47, Article No. 66. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Li, G., Li, D., Yu-an, F., et al. (2021) Synergistic Effect of Chidamide and Venetoclax on Apoptosis in Acute Myeloid Leukemia Cells and Its Mechanism. Annals of Translational Medicine, 9, Article No. 1575. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Chen, N.C., Borthakur, G. and Pemmaraju, N. (2021) Bromodomain and Extra-Terminal (BET) Inhibitors in Treating Myeloid Neoplasms. Leukemia & Lymphoma, 62, 528-537. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Djamai, H., Berrou, J., Dupont, M., et al. (2021) Biological Effects of BET Inhibition by OTX015 (MK-8628) and JQ1 in NPM1-Mutated (NPM1c) Acute Myeloid Leukemia (AML). Biomedicines, 9, Article No. 1704. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Pericole, F.V., Lazarini, M., de Paiva, L.B., et al. (2019) BRD4 Inhibition Enhances Azacitidine Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Frontiers in On-cology, 9, Article No. 16. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Wellbrock, J., Behrmann, L., Muschhammer, J., et al. (2021) The BET Bromodomain Inhibitor ZEN-3365 Targets the Hedgehog Signaling Pathway in Acute Myeloid Leukemia. Annals of Hematology, 100, 2933-2941. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
van Gils, N., Martiañez Canales, T., Vermue, E., et al. (2021) The Novel Oral BET-CBP/p300 Dual Inhibitor NEO2734 Is Highly Effective in Eradicating Acute Myeloid Leukemia Blasts and Stem/Progenitor Cells. Hemasphere, 5, e610. [Google Scholar] [CrossRef]
|
|
[25]
|
Borthakur, G., Odenike, O., Aldoss, I., et al. (2021) A Phase 1 Study of the Pan-Bromodomain and Extraterminal Inhibitor Mivebresib (ABBV-075) Alone or in Combination with Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia. Cancer, 127, 2943-2953. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Lee, S., Urman, A. and Desai, P. (2019) Emerging Drug Profile: Krebs Cycle and Cancer: IDH Mutations and Therapeutic Implications. Leukemia & Lymphoma, 60, 2635-2645. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Stein, E.M., DiNardo, C.D., Fathi, A.T., et al. (2021) Ivo-sidenib or Enasidenib Combined with Intensive Chemotherapy in Patients with Newly Diagnosed AML: A Phase 1 Study. Blood, 137, 1792-1803. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
DiNardo, C.D., Schuh, A.C., Stein, E.M., et al. (2021) Enasidenib plus Azacitidine versus Azacitidine Alone in Patients with Newly Diagnosed, Mutant-IDH2 Acute Myeloid Leukaemia (AG221-AML-005): A Single-Arm, Phase 1b and Randomised, Phase 2 Trial. The Lancet Oncology, 22, 1597-1608. [Google Scholar] [CrossRef]
|
|
[29]
|
McMurry, H., Fletcher, L. and Traer, E. (2021) IDH Inhibi-tors in AML-Promise and Pitfalls. Current Hematologic Malignancy Reports, 16, 207-217. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Fang, Y., Liao, G. and Yu, B. (2019) LSD1/KDM1A Inhibitors in Clinical Trials: Advances and Prospects. Journal of Hematology & Oncology, 12, Article No. 129. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Wass, M., Göllner, S., Besenbeck, B., et al. (2021) A Proof of Concept Phase I/II Pilot Trial of LSD1 Inhibition by Tranylcypromine Combined with ATRA in Refractory/Relapsed AML Patients Not Eligible for Intensive Therapy. Leukemia, 35, 701-711. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Zhang, S., Liu, M., Yao, Y., et al. (2021) Targeting LSD1 for Acute Myeloid Leukemia (AML) Treatment. Pharmacological Research, 164, Article ID: 105335. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Grieselhuber, N.R. and Mims, A.S. (2021) Novel Targeted Ther-apeutics in Acute Myeloid Leukemia: an Embarrassment of Riches. Current Hematologic Malignancy Reports, 16, 192-206. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Zhang, W., Zhao, C., Zhao, J., et al. (2018) Inactivation of PBX3 and HOXA9 by Down-Regulating H3K79 Methylation Represses NPM1-Mutated Leukemic Cell Survival. Theranostics, 8, 4359-4371. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Lonetti, A., Indio, V., Laginestra, M.A., et al. (2020) Inhibition of Methyl-transferase DOT1L Sensitizes to Sorafenib Treatment AML Cells Irrespective of MLL-Rearrangements: A Novel Thera-peutic Strategy for Pediatric AML. Cancers (Basel), 12, Article No. 1972. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Eich, M.L., Athar, M., Ferguson, J.E., et al. (2020) EZH2-Targeted Therapies in Cancer: Hype or a Reality. Cancer Research, 80, 5449-5458. [Google Scholar] [CrossRef]
|
|
[37]
|
Porazzi, P., Petruk, S., Pagliaroli, L., et al. (2022) Targeting Chemotherapy to Decondensed H3K27me3-Marked Chromatin of AML Cells Enhances Leukemia Suppression. Cancer Research, 82, 458-471. [Google Scholar] [CrossRef]
|